3//SEC Filing
Casdin Private Growth Equity Fund, L.P. 3
Accession 0000899243-21-024254
CIK 0001840574other
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 7:22 PM ET
Size
5.4 KB
Accession
0000899243-21-024254
Insider Transaction Report
Form 3
Holdings
Series B Preferred Stock
→ Common Stock (620,571 underlying)
Footnotes (2)
- [F1]The Series B Preferred Stock is convertible into common stock on a 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- [F2]The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001823061
Filing Metadata
- Form type
- 3
- Filed
- Jun 15, 8:00 PM ET
- Accepted
- Jun 16, 7:22 PM ET
- Size
- 5.4 KB